For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Who we are

A cooperative oncology group that designs and administers cancer clinical trials

The Canadian Cancer Trials Group (CCTG) is a cooperative oncology group that designs and administers clinical trials in cancer therapy, supportive care and prevention across Canada. We support a collaborative network of researchers, physicians, scientists and statisticians internationally recognized for finding the treatments that give people with cancer longer, better quality lives.

Created in 1980, the group has run trials resulting in major, life-saving breakthroughs in breast, colorectal, blood, lung, ovarian, brain and prostate cancer. The network is made of more than 80 member institution, comprising over 2100 Canadian investigators who have facilitated over 500 trials in more than 40 countries.

CCTG’s Central Operations and Statistics Office is located in the Cancer Research Institute at Queen’s University, with in-house faculty researchers that include clinician scientists, researchers in community health and epidemiology, and biostatisticians.

The group is proud to be one of the national programmes of the Canadian Cancer Society (CCS), the only non-American partner of the US National Clinical Trials Network and collaborators with research cooperative groups around the world. These international partnerships are central to the success of their cancer clinical trials and crucial to the advancement of the cancer research agenda in Canada.

Our mission

To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.

Find out more in this story: CCTG at Queen's plays a central role in the progress of cancer care

Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competition

Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Spring 2020 competition.

More >>
An interview with Senior Investigator Annette Hay

An interview with Senior Investigator Annette Hay

Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.

More >>

Pregnancy and the safety of Interrupting therapy for young women with breast cancer

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy.

More >>